https://www.fda.gov/media/136534/download
Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease
https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000041755775&categorieLien=id
Advisory issued by The National Task Force for Covid-19 constituted by the Indian Council of Medical Research (adopted by Ministry of Health 22 March, 2020) recommends the use of Hydroxychloroquine for prophylaxis of SARS-CoV-2 infection for selected individuals:
https://www.ncbi.nlm.nih.gov/pubmed/32164085
A multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus
https://doi.org/10.1016/j.ipej.2020.04.003
American College of Cardiology, March 29, 2020
Baseline (Before commencing treatment, do the following):
Relative contraindications (subject to modification based on potential benefits of therapy):
Ongoing monitoring, dose adjustment and drug discontinuation:
Baseline (Before commencing treatment, do the following):
Relative contraindications (subject to modification based on potential benefits of therapy):
Ongoing monitoring, dose adjustment and drug discontinuation:
Risk Factors | Points |
Age ≥68 yrs | 1 |
Female sex | 1 |
Loop diuretic | 1 |
Serum K+ ≤3.5 mEq/L | 2 |
Admission QTc ≥450 ms | 2 |
Acute MI | 2 |
≥2 QTc-prolonging drugs | 3 |
Sepsis | 3 |
Heart failure | 3 |
One QTc-prolonging drug | 3 |
Maximum Risk Score | 21 |
K+ indicates potassium; and MI, myocardial infarction. |
A Tisdale score of ≤ 6 predicts low risk, 7-10 medium risk, and ≥ 11 high risk of drug-associated QT prolongation.